匹伐他汀内酯杂质 | 702680-17-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 匹伐他汀内酯杂质
• 英文名称: (S)-2-(3-{1-[(4-isopropylphenyl)acetyl]piperidin-3-yl}phenoxy)-2-methylpropionic acid
• 英文别名: 2-methyl-2-[3-[(3S)-1-[2-(4-propan-2-ylphenyl)acetyl]piperidin-3-yl]phenoxy]propanoic acid
• CAS: 702680-17-9
• 化学式: C₂₆H₃₃NO₄
• 分子量: 423.552
• InChiKey: OISHBINQIFNIPV-JOCHJYFZSA-N

物化性质

• 熔点：
  >70°C (dec.)
• 溶解度：
  二甲基亚砜：≥80mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• WGK Germany：
  3

文献信息

• [EN] PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS<br/>[FR] COMPOSES DE PIPERIDINE PHENYLE A SUBSTITUTION PHENYLE S'UTILISANT COMME ACTIVATEURS DE PPAR
  申请人：PFIZER PROD INC

  公开号：WO2004048334A1

  公开（公告）日：2004-06-10

  PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.

  PPARα激动剂，含有这类化合物的药物组合物以及利用这类化合物提高特定血浆脂质水平，包括高密度脂蛋白胆固醇，并降低其他特定血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，并据此治疗由高密度脂蛋白胆固醇水平低和/或低密度脂蛋白胆固醇和甘油三酯水平高加重的疾病，如动脉粥样硬化和心血管疾病，在哺乳动物，包括人类中的应用。
• PPAR activators
  申请人：Pfizer Inc

  公开号：US20040157885A1

  公开（公告）日：2004-08-12

  PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.

  PPAR alpha激动剂，含有这些化合物的药物组合物以及使用这些化合物提高某些血浆脂质水平，包括高密度脂蛋白胆固醇并降低其他某些血浆脂质水平，例如低密度脂蛋白胆固醇和甘油三酯，并因此治疗由低HDL胆固醇水平和/或高LDL胆固醇和甘油三酯水平加重的疾病，如动脉粥样硬化和心血管疾病，在哺乳动物中，包括人类。
• PPAR ACTIVATORS
  申请人：Bagley W. Scott

  公开号：US20070191429A1

  公开（公告）日：2007-08-16

  PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.

  PPAR alpha激动剂，含有这种化合物的制药组合物以及使用这种化合物提高某些血浆脂质水平，包括高密度脂蛋白胆固醇和降低某些其他血浆脂质水平，如低密度脂蛋白胆固醇和三酰甘油，因此治疗低密度脂蛋白胆固醇和/或高三酰甘油水平加重的疾病，例如动脉粥样硬化和心血管疾病，在哺乳动物，包括人类中使用。
• PROPHYLACTIC AGENT AND/OR THERAPEUTIC AGENT FOR CATARACT, MEDICINAL COMPOSITION FOR PREVENTING AND/OR TREATING CATARACT, USE OF PPAR ACTIVATOR FOR PRODUCING SAME, AND EYEDROPS
  申请人：University of Fukui

  公开号：EP3733203A1

  公开（公告）日：2020-11-04

  Provided are agents for prevention and therapeutic treatment of cataract that act by a different mechanism from conventional agents, and use of a PPAR activator for production of such agents. An agent for prevention and/or therapeutic treatment of cataract, containing a PPAR activator as an active ingredient, is used.

  本发明提供了预防和治疗白内障的药剂，其作用机理与传统药剂不同，还提供了使用 PPAR 激活剂生产此类药剂的方法。一种用于预防和/或治疗白内障的药剂含有 PPAR 激活剂作为活性成分。
• Combination therapy comprising an ACC inhibitor
  申请人：Gilead Sciences, Inc.

  公开号：US10980810B2

  公开（公告）日：2021-04-20

  The present disclosure provides methods and compositions for treating, stabilizing or lessening the severity or progression of a non-alcoholic fatty liver disease.

  本公开提供了治疗、稳定或减轻非酒精性脂肪肝的严重程度或进展的方法和组合物。